Search results
Novavax, With A 369% Gain, Tears Ahead Again On A Key FDA Move
Investor's Business Daily· 1 day agoIn a filing with the Securities and Exchange Commission, Novavax said the FDA said it completed its...
FDA advisers: Next COVID shots should target variants with JN.1 lineage | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 3 days agoAdvisers to the U.S. Food and Drug Administration today unanimously voted in favor of recommending...
COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say
Reuters via AOL· 2 days ago(Reuters) -Advisers to the U.S. Food and Drug Administration on Wednesday unanimously voted in favor...
Will there be a new Covid vaccine in the fall?
NBC News via Yahoo News· 2 days agohe added. The FDA is expected to make a final decision soon on which strain it will advise drugmakers to target. That will kickstart production of the...
New Covid Boosters Get a Thumbs-Up From FDA. Vaccine Stocks Are Wavering.
Barrons.com· 1 day agoDrugmakers are aiming to launch this year’s shots by the beginning of September but have been...
70,000+ Zantac lawsuits are greenlit by a Delaware judge
Fast Company Magazine· 4 days agoThe ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a...
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say
Reuters· 2 days agoThis was disclosed in presentations by the companies ahead of a meeting of the U.S. Food and Drug ...
Novavax's stock surges almost 300% in the past month
AOL· 1 day agoNovavax stock (NVAX) is on a tear — soaring nearly 300% in the past month to $19.56 per share — following several pieces of good news. The Food and Drug ...
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
Reuters· 4 days agoVaccine makers should consider targeting one of the currently dominant JN.1 variants and...
Is Moderna Stock a Buy Now That It's a 2-Product Company?
Motley Fool via Yahoo Finance· 5 days agoAbrysvo, another RSV vaccine from Pfizer, also earned approval last May for those 60 or older....
